Further Weakness as Zai Lab (NASDAQ:ZLAB) Drops 8.9% This Week, Taking Three-year Losses to 61%
Further Weakness as Zai Lab (NASDAQ:ZLAB) Drops 8.9% This Week, Taking Three-year Losses to 61%
Zai Lab Limited (NASDAQ:ZLAB) shareholders should be happy to see the share price up 27% in the last quarter. But over the last three years we've seen a quite serious decline. Regrettably, the share price slid 61% in that period. So the improvement may be a real relief to some. While many would remain nervous, there could be further gains if the business can put its best foot forward.
再鼎医药有限公司(纳斯达克:ZLAB)股东应该会对股价在上个季度上涨27%感到高兴。 但在过去三年中,我们看到股价有相当严重的下滑。 不幸的是,在此期间股价下跌了61%。 所以这种改善可能对一些人来说是一个真正的 relief。 虽然许多人可能会保持紧张,但如果业务能够尽善尽美,可能还有进一步的涨幅。
With the stock having lost 8.9% in the past week, it's worth taking a look at business performance and seeing if there's any red flags.
由于股票在过去一周下跌了8.9%,值得关注一下业务表现,看看是否有任何风险信号。
Zai Lab isn't currently profitable, so most analysts would look to revenue growth to get an idea of how fast the underlying business is growing. Shareholders of unprofitable companies usually desire strong revenue growth. That's because it's hard to be confident a company will be sustainable if revenue growth is negligible, and it never makes a profit.
再鼎医药目前尚未盈利,因此大多数分析师会关注营收增长,以了解基础业务增长的速度。 不盈利公司的股东通常希望看到强劲的营业收入增长。 这是因为如果营业收入增长微不足道且公司从未盈利,很难对公司可持续性感到自信。
In the last three years, Zai Lab saw its revenue grow by 31% per year, compound. That is faster than most pre-profit companies. The share price has moved in quite the opposite direction, down 17% over that time, a bad result. It seems likely that the market is worried about the continual losses. When we see revenue growth, paired with a falling share price, we can't help wonder if there is an opportunity for those who are willing to dig deeper.
在过去三年中,再鼎医药的营业收入年均增长31%。 这比大多数未盈利公司要快。 在这段时间内,股价却大幅下跌了17%,结果不佳。 看起来市场担心持续的亏损。 当我们看到营业收入增长而股价下跌时,我们不禁想知道是否对愿意深入研究的人来说存在机会。
You can see below how earnings and revenue have changed over time (discover the exact values by clicking on the image).
您可以在下面看到盈利和营业收入随时间的变化(通过点击图片发现确切值)。
Zai Lab is a well known stock, with plenty of analyst coverage, suggesting some visibility into future growth. If you are thinking of buying or selling Zai Lab stock, you should check out this free report showing analyst consensus estimates for future profits.
再鼎医药是一只知名的股票,受到众多分析师的关注,这表明未来增长有一定的可见性。如果你正在考虑买入或卖出再鼎医药的股票,你应该查看这份免费的报告,报告中显示了分析师对未来利润的共识估计。
A Different Perspective
不同的视角
While the broader market gained around 30% in the last year, Zai Lab shareholders lost 12%. However, keep in mind that even the best stocks will sometimes underperform the market over a twelve month period. Unfortunately, last year's performance may indicate unresolved challenges, given that it was worse than the annualised loss of 6% over the last half decade. Generally speaking long term share price weakness can be a bad sign, though contrarian investors might want to research the stock in hope of a turnaround. It's always interesting to track share price performance over the longer term. But to understand Zai Lab better, we need to consider many other factors. Consider risks, for instance. Every company has them, and we've spotted 1 warning sign for Zai Lab you should know about.
虽然大盘在过去一年上涨了约30%,但再鼎医药的股东却损失了12%。然而,请注意,即便是最好的股票,有时在一年内也可能会表现不佳。不幸的是,去年的表现可能表明存在未解决的挑战,因为其表现甚至低于过去五年年化损失的6%。一般而言,长期的股价疲弱可能是一个不好的信号,尽管逆向投资者可能希望研究这只股票,期待其反弹。追踪股价在更长期内的表现总是很有趣。但要更好地理解再鼎医药,我们需要考虑许多其他因素。比如,考虑风险。每家公司都有风险,而我们发现再鼎医药有1个警示信号,你应该了解。
We will like Zai Lab better if we see some big insider buys. While we wait, check out this free list of undervalued stocks (mostly small caps) with considerable, recent, insider buying.
如果我们看到一些大额内部人士买入,我们会更喜欢再鼎医药。在我们等待的同时,请查看这份免费的低估股票列表(主要是小型股),这些股票最近有相当大的内部人士买入。
Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on American exchanges.
请注意,本文中引用的市场回报反映了当前在美国交易所上市股票的市场加权平均回报。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
对本文有反馈?对内容有疑虑?请直接与我们联系。或者,发送电子邮件至 editorial-team (at) simplywallst.com。
这篇来自Simply Wall St的文章是一般性的。我们根据历史数据和分析师预测提供评论,采用无偏见的方法,我们的文章并不旨在提供财务建议。它不构成对任何股票的买入或卖出建议,也未考虑到您的目标或财务状况。我们旨在为您提供以基本数据驱动的长期分析。请注意,我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St在提到的任何股票中均没有持仓。